Both the NAT10‐specific antagonist and a genetic knockdown of NAT10 can impede BLCA progression, which indicates that targeting NAT10 might be a novel strategy for treating BLCA. This evidence concerns the gene NAT10 and bladder transitional cell carcinoma.